Venture Capital

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

Private equity firm Oakline acquires a major affordable housing manager. Is this the future of community management or a simple play for scale?

A stealth startup just raised $24M from tech's biggest names to solve AI's hardware crisis. Their plan: use AI to design chips, making custom silicon accessible to all.

Beyond amyloid plaques, a new therapy tackles Alzheimer's by reducing inflammation. Longeveron's latest data offers a glimpse into a regenerative future.

As layoffs continue, a new guide reveals the critical mistake leaders make: ignoring the employees who stay. Here's how to rebuild trust and retain talent.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

A public company is offering a volatile mix of OpenAI, Worldcoin, and MrBeast. We deconstruct the high-risk, high-reward strategy behind its unique treasury.

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

A DoW contract for in-orbit refueling thrusts Quantum Space into the spotlight, promising to redefine space warfare and ignite the orbital logistics economy.

With a fresh $260M, Dream is building AI for nations to own. But as governments rush for digital autonomy, are we creating a new digital iron curtain?

UAE-based Robo.ai is acquiring a venture builder with a $60M all-stock deal tied to a staggering $2.4B revenue target. Is this visionary ecosystem-building or a high-risk bet?

With 2.25M developers and advanced hybrid cloud adoption, India isn't just joining the cloud native world; it's rewriting the rules for global innovation.

A startup's new MR glasses challenge Microsoft HoloLens, but the real story is its bold play to fuel the physical AI revolution with specialized data hardware.

Netlist's new patent lawsuits over HBM and DDR5 memory could disrupt the AI supply chain, putting the tech giants' critical components in legal peril.

Office Properties Income Trust emerges from bankruptcy with $714M less debt and new owners. Is its strategic overhaul a model for a sector in crisis?

As RESTEM presents at BIO 2026, the company showcases its novel cell therapies aiming to reprogram the immune system, not just manage symptoms.

Sharon AI's massive financing reveals a deeper story: a global race to build the physical backbone for AI, fueled by visionary bets and cautious capital.

Activist investor Saba Capital has ousted the board of Impax Environmental Markets, a stunning victory fueled by chronic underperformance. What does this mean?

As enterprises deploy autonomous AI agents, a new class of threats emerges. A startup founded by Cisco veterans says it can stop attacks before they happen.